Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
Shigeki Nanjo(Kanazawa University), Trever G. Bivona(University of California, San Francisco)
Cited by 53
Related Papers
Targeting Oncogenic BRAF: Past, Present, and Future
|Cancers|2019|241
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
|Nature Communications|2024|84
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells
|Oncotarget|2015|58